Table 2. Characteristics of the study population.

	Case group		Control group
Number of patients	13	(100)	100	(100)
Sex
Male	8	(61.5)	41	(41.0)
Female	5	(38.5)	59	(59.0)
Age, years	56.4	(15.9)	52.9	(21.8)
Agreement between diagnosis with ICD-10 code and final diagnosis	8	(61.5)	85	(85.0)
Referral from another hospital	1	(7.7)	24	(24.0)
Clinical course for SJS/TEN at the Department of Dermatology
Item 2: Hospitalization	13	(100)	32	(32.0)
Item 3: Skin biopsy	12	(92.3)	12	(12.0)
Item 4: Systemic treatment for SJS/TEN	12	(92.3)	8	(8.0)
Steroid therapy	12	(92.3)	8	(8.0)
Intravenous immunoglobulin therapy	3	(23.1)	0	(0.0)
Plasma exchange therapy	0	(0.0)	0	(0.0)
Medical encounters for mucocutaneous lesions from SJS/TEN
Item 5: Presence of medical encounters for mucocutaneous lesions from SJS/TEN	12	(92.3)	6	(6.0)
ICD-10 code for SJS/TEN at the Department of Ophthalmology or Dentistry, or for mucocutaneous lesions (no limitation on department)	11	(84.6)	2	(2.0)
Steroid eyedrops or ophthalmic ointment	8	(61.5)	2	(2.0)
Slit-lamp microscopy	10	(76.9)	6	(6.0)
Exclusion of paraneoplastic pemphigus
Item 6a: Prescription of anti-cancer drug	2	(15.4)	12	(12.0)
Item 6b: Anti-desmoglein 1 or 3 antibody test ≥2	0	(0.0)	2	(2.0)

ICD-10, International Classification of Diseases, 10th Edition; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.

Data are presented as mean (SD) or number of subjects (%).